5-HT2A/2C Receptor Modulators Without Hallucinogenic Cardiotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic drugs like psilocybin and LSD are hallucinogenic and cardiotoxic, limiting their widespread use for treating psychological disorders due to the need for clinical administration and potential health risks, while non-hallucinogenic and non-cardiotoxic tryptamine analogs or mimetics that modulate the 5-HT2A receptor are lacking.
Innovation Solution
Development of hallucinogenic and non-hallucinogenic serotonin receptor agonist compounds, represented by Formula I, which can be administered outside a clinical setting and do not exhibit cardiotoxicity, allowing for daily/weekly therapy at home.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychedelic drugs like psilocybin and LSD are used to treat psychological disorders, then therapeutic effect is improved, but cardiotoxicity and hallucinogenic effects worsen
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of tryptamine compounds - specifically changing substituents at positions R1, R2, R3, R4, R5, R6, and R7 of the indole ring system. These structural parameter changes produce compounds with altered pharmacological profiles that maintain 5-HT2A receptor affinity while reducing cardiotoxicity and hallucinogenic effects
Solution Approach 2:
The patent applies local quality by introducing specific substituents at particular positions on the indole ring. For example, placing electron-withdrawing groups at R2 or R3 positions, or specific alkyl groups at R4 and R5, creates localized chemical modifications that selectively influence receptor binding properties and safety profiles
2Reliability
If psychedelic drugs are administered in clinical settings, then safety is improved, but ease of operation and accessibility worsen
Solution Approach 1:
The patent extracts the harmful hallucinogenic and cardiotoxic properties from the therapeutic mechanism by designing compounds that selectively modulate 5-HT2A receptors without producing psychedelic effects. This allows the therapeutic benefits to be separated from the adverse effects requiring clinical supervision
Solution Approach 2:
The patent introduces non-hallucinogenic tryptamine analogs as intermediary compounds that mediate the therapeutic effect through 5-HT2A receptor modulation without producing the strong psychedelic effects of classical psychedelics, thereby reducing the need for clinical setting administration
Data Source
AI summary
Hallucinogenic and non-hallucinogenic serotonin receptor agonists are disclosed herein in addition to methods of making and using the same.